2026 ARVO Annual Meeting
Archives for PosterPublications & Posters
VIEW:
The below publications outline research from Qlaris Bio's initial formulation, QLS-101. Based on this research, we have now developed a new formulation of our program, called QLS-111.
2026 American Glaucoma Society Annual Meeting
Safety, tolerability, and ocular hypotensive efficacy of QLS-111, a novel topical ATP-sensitive potassium channel opener
2025 ISER/BrightFocus Foundation Glaucoma Symposium
QLS-111 Safely and Effectively lowered intraocular pressure in two phase 2 clinical trials, Osprey and Apteryx
2025 ISER/BrightFocus Foundation Glaucoma Symposium
QLS-111-FDC, a fixed dose combination of QLS-111 with latanoprost, effectively lowers IOP in a normotensive preclinical mouse model
2025 World Glaucoma Congress
Preclinical assessment of QLS-111, a novel ATP-sensitive potassium channel opener, alone and in combination with approved ocular hypotensive drugs
2025 World Glaucoma Congress